$STX

MOSLEY WILLIAM D sold $1.5M of STX

MOSLEY WILLIAM D (CEO) sold 1,598 shares of Seagate Technology Holdings plc (STX) at $922.95 ($1.47M total) on 2026-06-01 under a Rule 10b5-1 trading plan.

Original reporting
SEC EDGAR · MOSLEY WILLIAM D
Published Jun 2, 2026, 9:16 PM UTC
Analysis
alphai AI DeskAI-generated
Added to alphai Jun 2, 2026, 9:19 PM UTC. Informational, not investment advice.
How this was made
alphai summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
alphai market briefInsider activity
Primary signal
$STX
Neutral
medium confidence
Mentioned
$STX
Relevance
6/10
alphai data visualization · based on SEC EDGAR
Decision brief

The 30-second read

$STXNeutralLow
01

Why it matters

The disclosure provides incremental information about insider activity but does not, by itself, change Seagate’s fundamentals or forward outlook.

02

Market read

Traders may monitor for patterns in insider activity, but this single Form 4 is unlikely to drive a material repricing.

03

What to watch

The sale size is small relative to typical large-cap liquidity, and the disclosure does not indicate intent beyond the pre-arranged plan.

Relevance 6/10Novelty 6/10Timing: Filed today; reflects sale executed 2026-06-01.

Background

SEC Form 4 reports insider transactions for Seagate Technology Holdings plc; this one is an open-market sale by the CEO under a pre-arranged 10b5-1 plan.

Company-level read

Ticker impact

$STXNeutralMedium confidence
Context

Seagate CEO William D. Mosley sold $1.47M of STX shares in an open-market transaction under a pre-arranged 10b5-1 plan.

Expected impact

Low likelihood of sustained price impact; any effect is likely short-lived unless follow-on selling accelerates.

Evidence & confidence

The filing is an ownership-change disclosure with a stated 10b5-1 plan, which typically reduces the signal of new negative information.

Market effects

Minimal; this is company-specific insider activity without sector-wide read-through.

None indicated.

None indicated.

Counterpoint

Even with a 10b5-1 plan, repeated insider selling can still be read as reduced confidence by some traders.

Key entities

  • Seagate Technology Holdings plc

    STX; CEO William D. Mosley sold 1,598 shares for ~$1.47M under a 10b5-1 plan.

Full insider trading history

This story covers one filing. See everything behind it: every insider buy and sell on record, 10b5-1 plans, late filings, and which officers and directors are trading.

Related articles

$NVDAHighAI 9/10

Markets News, Aug. 27, 2026: Nvidia Stock Powers Higher After Earnings, Driving Tech Gains; Nasdaq Closes Sharply Higher

Nvidia (NVDA) reported strong Q2 earnings and raised Q3 revenue guidance to $108B, driving its stock up 9% and boosting tech sector gains. Nasdaq, S&P 500, and Dow closed higher. Other notable movers include Okta (OKTA) +29%, Salesforce (CRM) +23%, and CrowdStrike (CRWD) +20%. Corporate profits surged $400B in Q2, partly due to $71B in tariff refunds.

$STXMed

Moody’s upgrades Seagate Data rating on AI demand strength

Moody's upgraded Seagate Data's corporate family rating to Ba1 from Ba2, citing AI-driven demand for high-capacity HDDs. The agency expects revenues to grow over 30% annually, reaching $20B, and debt to EBITDA to fall below 0.5x. Seagate faces risks from revenue concentration and pricing pressures. The company had $1.7B in cash and access to a $1.3B credit facility as of July 2026.

$MRNAHighAI 8/10

3 Stocks Soared, 3 Stocks Slumped

Moderna (MRNA) surged 176.97% to $174.38 after reporting positive trial results for a cancer therapy with Merck (MRK). Estee Lauder (EL) rose 16% to $98.01 with revenue up 6.5% Y/Y. MicroStrategy (MSTR) gained 12.68% as Bitcoin prices rose. Nebius (NBIS) fell 10% after a $4.5B convertible note offering. Seagate (STX) dropped 8% to $832.56.

$STXMed

REG - Shield Therapeutics - Shield assumes full control of ACCRUFeR® in the US

Shield Therapeutics (STX) will take full control of ACCRUFeR® in the US from Viatris by September 30, 2026. The deal is expected to boost Shield's profitability and growth, with no upfront payments to Viatris. Shield will pay royalties on US net sales, ranging from high single digits to mid-teens over five years, and retain all gross profits from US sales. The transaction is anticipated to enhance Shield's financial profile and support its path to sustained profitability.